HENNEMAN JOHN B III 4

What Happened
John B. Henneman III, a director of Orthofix Medical Inc. (OFIX), was granted 14,965 deferred stock units on June 10, 2026. The units were awarded at $0.00 (i.e., no cash purchase price) and each deferred stock unit represents a contingent right to receive one share of Orthofix common stock. The award vests in full on the first anniversary of the grant date, subject to continued service.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (no late filing indicated).
• Transaction type/code: Award/Grant (A).
• Units granted: 14,965 deferred stock units; grant price reported as $0.00.
• Beneficial position after grant: includes 48,347 previously reported deferred stock units (footnote), for a total of 63,312 deferred stock units now reported.
• Footnote F1: Units vest in full on the first anniversary, each unit = contingent right to one share; vested units convert to common stock within 45 days of the reporting person’s termination of service.
• Footnote F2: The total includes 48,347 previously reported deferred stock units.

Context
This was an equity compensation award to a board member (routine director compensation), not an open-market purchase or sale. Deferred stock units are not immediate shares — they vest later based on service and convert to stock under the terms noted above. Such awards are common for aligning directors’ interests with shareholders and do not by themselves indicate a personal buy/sell decision.